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MinireviewDendritic Cells, BAFF, and APRIL:
Innate Players in Adaptive
Antibody Responses
Ig V-region hypermutation and B cell selection in germi-
nal centers. The two pathways to adaptive antibody
production are not mutually exclusive and in most re-
sponses where T cell help is elicited they run in tandem.
It has been suspected that accessory cells might also
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play a role in triggering B cells to grow as plasmablasts.2 The Medical Genome Center
Dendritic cells clearly do this through their role in primingJohn Curtin School of Medical Research
T cells. In addition, data from studies in vitro indicateCanberra, ACT
dendritic cells can influence B cell activation (Colino etAustralia
al., 2002; Fayette et al., 1998; Litinskiy et al., 2002) and
can transport intact antigen to B cells (Wykes et al.,
1998). Previously, it has been shown that plasmacytoidThe first antibody produced in bacterial or viral infec-
dendritic cells, which are powerful producers of inter-tion results from B cell growth as plasmablasts. Den-
feron- (Asselin-Paturel et al., 2001), enhance antibodydritic cell-derived TNF-family ligands APRIL and/or
responses and induce nonselective Ig class switchingBAFF enhance plasmablast survival and differentiation
(Le Bon et al., 2001). In this issue of Immunity, Bala´zsto plasma cells. Expression of these ligands by den-
et al. provide direct evidence for the role of a subset ofdritic cells is promoted by innate immune signals that
blood-derived dendritic cells in the transport of killedcan convert subliminal B cell activation to a produc-
bacteria to B cells. They show that these dendritic cellstive response. While this may be lifesaving in the face
are critical for a T cell-independent type-2 (TI-2) extrafol-of infection, it can predispose to autoantibody pro-
licular antibody response by promoting plasmablast sur-duction.
vival. This effect is markedly impaired by neutralizing B
cell activating factor (BAFF) and its closely related tumorFirst line adaptive humoral defense involves antigen-
necrosis factor family member APRIL (a proliferation-induced activation of B cells to grow as plasmablasts
inducing ligand).and secrete antibody. A critical feature of these extrafol-
BAFF and APRIL in B Cell Development,licular antibody responses is the relatively short lag
Activation, and Survivalphase between exposure to antigen and the onset of
BAFF (Blys) and APRIL influence B cell maturation andantibody secretion. This can be vital in limiting the
survival at a number of levels. B cells are known tospread of both viral and bacterial infections.
express three receptors for BAFF: BAFF-R, TACI (trans-The Sequence of Events in Extrafollicular
membrane activator and CAML-interactor), and BMCAAntibody Responses
(B cell maturation antigen); of these, TACI and BMCAThe following successive steps are associated with T
also bind APRIL. BAFF and to a lesser extent APRIL arecell-dependent extrafollicular responses (Figure 1).
expressed in secondary lymphoid organs that supportFirst, B cells that bind antigen through their B cell recep-
extrafollicular antibody responses, and BAFF expres-tors are induced to move rapidly to the T zones of sec-
sion is particularly associated with macrophages andondary lymphoid tissue and acquire a propensity to seek
dendritic cells. The expression and functions of theseout primed T cells (Liu et al., 1991). Second, cognate
molecules have recently been reviewed in detail (Do and
interaction between these cells triggers the B cells to
Chen-Kiang, 2002; Mackay and Browning, 2002; Rolink
enter cell cycle and migrate yet again to either splenic
and Melchers, 2002). BAFF-deficient mice and mice defi-
extrafollicular foci (Jacob et al., 1991) or the medullary cient in BAFF-R have a block in maturation of transitional
cords of lymph nodes (Luther et al., 1997). Third, the 1 to transitional 2 B cells (Schiemann et al., 2001; Yan
activated B cells differentiate to plasmablasts (prolifer- et al., 2001a). This may in part reflect a requirement for
ating cells with plasmacytoid features) which grow in BAFF and APRIL for continued survival of recirculating
these sites in the absence of T cells (Gulbranson-Judge and marginal zone B cells, which are profoundly de-
and MacLennan, 1997; Luther et al., 1997) and further pleted within days of starting to neutralize BAFF and
differentiate after about 3 days into fully secreting APRIL with soluble BMCA (Thompson et al., 2000) or
plasma cells (Sze et al., 2000). Many but not all of the TACI-Ig (Schneider et al., 2001). Impairment of signaling
plasma cells produced in these responses are short lived through TACI has been reported to be associated with
(Smith et al., 1996; Sze et al., 2000). T cell-independent reduced TI-2 and to a lesser extent T-dependent anti-
antigens also trigger extrafollicular plasmablast growth, body responses (von Bulow et al., 2001; Yan et al.,
where the same sequence is followed without the inter- 2001b). Conversely, TI-2 responses are enhanced in
vention of T cells (Vinuesa et al., 1999b). The B cells mice overexpressing APRIL or BAFF (Stein et al., 2002).
move through four microenvironments during this re- During the early stage of B cell activation, in vitro BAFF
sponse (Figure 1). In the first three of these, dendritic signaling increases the numbers of antigen-activated B
cells play important roles (Table 1). Extrafollicular re- cells that survive to enter cell cycle (Do and Chen-Kiang,
sponses contrast with the slower pathway to far more 2002). Also, both BAFF and APRIL induce nonselective
sustained antibody production, which is associated with Ig class switch recombination (Litinskiy et al., 2002) rem-
iniscent of that induced by type-I interferons in mice (Le
Bon et al., 2001).3 Correspondence: i.c.m.maclennan@bham.ac.uk
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Figure 1. The Four Microenvironments of Ex-
trafollicular Antibody Responses
When marginal zone or other B cells specifi-
cally bind antigen carried either free in the blood
or transported by B220CD11clowCD11bhigh
blood dendritic cell precursors (pDC1), they
rapidly migrate to the T zone. There, they are
efficient at interacting with primed T cells and
receive the signals that induce them to be-
come plasmablasts. The plasmablasts mi-
grate to extrafollicular foci where they prolif-
erate in the presence of CD11chigh dendritic
cells and, after about 3 days, differentiate into
plasma cells. The splenic red pulp has a finite
capacity to sustain a proportion of the plasma
cells generated for extended periods. Den-
dritic cell involvement in each of these micro-
environments is summarized in Table 1.
Induction and Control of Extrafollicular which represses the expression of genes involved in B
cell receptor signaling and proliferation while allowingAntibody Responses
Much is known of the way B cells are activated by B expression of genes required for plasma cell develop-
ment such as XBP-1 (Reimold et al., 2001, Shaffer et al.cell-receptor engagement and T cell help. By contrast,
relatively little is known of the signals that trigger B cells 2002). Those cells committed to form germinal centers
upregulate Bcl-6, which in turn suppresses the plas-to grow as extrafollicular plasmablasts as opposed to
B blasts, which proliferate in follicles and form germinal mablast program of differentiation by repressing
Blimp-1 (Fearon et al., 2001).centers. Although both types of growth are frequently
T cell dependent, there is no absolute T cell requirement BCR engagement in the presence of cytokines (with
or without the delivery of T cell signals) triggers theto trigger either pathway of growth (Vinuesa et al., 2000).
Once the signals for divergent differentiation are regis- plasmablast reaction. Information is now emerging of
factors that influence the control of plasmablast growthtered, key transcriptional regulators reinforce commit-
ment to one or the other pathway of differentiation. Thus, and survival and subsequent differentiation to plasma
cells. Cell cycle arrest seems to be required for success-differentiation to plasmablasts is regulated by expres-
sion of Blimp-1 (Mock et al., 1996; Shaffer et al., 2002), ful plasmablast differentiation to plasma cells. Blimp-1
Table 1. Dendritic Cell Involvement in the Microenvironments Associated with Extrafollicular Antibody Responses
Marginal Zone Intact antigen is transported by monocyte-derived (B220CD11bCD11clow)
dendritic cells and is available to be bound by B cells. Marginal zone B
cells are bathed by blood sinusoids; consequently, they also have access
to free antigen in the blood.
T Zone Dendritic cells with processed antigen have a critical role in priming T cells.
There may also be a role for a range of dendritic cells in reinforcing B
cell activation through their B cell receptors and cognate interaction with
primed T cells, e.g., by BAFF and APRIL secreted by monocyte-derived dendritic
cells. BAFF secretion can in turn be induced by type-I interferons produced
by plasmacytoid dendritic cells, on activation by viruses and bacterial CpG.
Focus of Plasmablast Growth Plasmablasts grow in association with the CD11chigh dendritic cells that are
typically found in this area. This is possibly the main site of BAFF and
APRIL influence on plasmablast survival and their transition to become
persistent plasma cells. T cells do not enter these foci.
Long-Lived Plasma Cells in the Red Pulp These plasma cells are found lying along fibrous bands and contiguous blood
vessels. The molecular and cellular basis of the signals that secure the
survival of these cells is unknown. Plasma cells from extrafollicular foci
compete with plasma cells coming from germinal centers for these sites.
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directly represses c-myc, which is required for B cell together with CD40 ligation and bacterial cell wall lipo-
proliferation and growth. It has also been shown that polysaccharide is a potent inducer of BAFF expression
plasmablasts generated in mice deficient in the p18Ink4c on in vitro-generated dendritic cells (Litinskiy et al.,
CDK inhibitor form hyperproliferating antibody-con- 2002). This points to a hypothetical scenario in which
taining plasmablasts that fail to differentiate into effi- bacteria induce plasmacytoid dendritic cells to produce
cient antibody-secreting cells (Tourigny et al., 2002). The type-I interferons, which induce BAFF and/or APRIL se-
number of cell cycles completed by plasmablasts does cretion from monocyte (pDC1)-derived DCs and their
not seem to be limited solely by stromal signals, for the migration into secondary lymphoid tissues.
end number of plasma cells produced in an unmanipu- Bala´zs et al. provide evidence that CD11clow, B220
lated extrafollicular response shows a direct correlation dendritic cells from the blood bind and transport the
with the number of B cells recruited into the response bacterial antigen to the marginal zone, where they make
(Sze et al., 2000). Thus splenic plasmablast growth in this accessible to B cells. Neutrophils and macrophages
extrafollicular antibody responses of normal mice is also take up the killed bacteria and accumulate in the
largely restricted to the junction zones between the T spleen, but do not induce an antibody response. Since
zone and red pulp, while in mice with BCR encoded by CD11clow antigen-transporting dendritic cells upregulate
a transgene, plasmablast growth can occur throughout CD11c on binding dead bacteria, they might be the pre-
the red pulp (Sze et al., 2000). By contrast, the capacity cursors of the CD11chigh cells found in extrafollicular foci.
of the spleen to sustain late plasmablast or plasma cell The de novo appearance of these dendritic cells at sites
survival is limited. Thus, in the situation where massive of plasmablast growth is shown by their appearance in
numbers of plasmablasts are generated in mice with previously rudimentary medullary cords during primary
transgenic B cell receptors, the number of plasma cells plasmablast growth (Vinuesa et al., 1999a). From Bala´zs
surviving more than 48 hr is no more than that in re- et al.’s study, it is not clear whether the survival signal
sponses in wild-type mice where peak plasmablast is delivered by the DCs at the time of antigen presenta-
numbers are far lower (Sze et al., 2000). Previous correla- tion to naive B cells in the marginal zone, or during
tive studies suggest that the stromal element limiting contact with plasmablasts while they grow in the extra-
plasmablast survival is a CD11chigh dendritic cell popula- follicular foci, or at both these stages.
tion normally found in splenic extrafollicular foci and the The signal transduction pathway triggered by BAFF
medullary cords of lymph nodes (Vinuesa et al., 1999a). and/or APRIL that prolongs plasmablast survival is still
The mechanism of support was not identified. Bala´zs not characterized. Impaired plasmablast survival is a
et al. (2002) now show that TACI-Fc-neutralizable mole- feature of the response of Btk-deficient marginal zone
cules secreted by the dendritic cells might sustain late B cells to TI-2 antigen. The antigen induces B cell trans-
plasmablasts during their differentiation to plasma cells. location to the outer T zone and growth, but although
The precise role of BAFF and APRIL in enhancing the the blasts start to upregulate Blimp-1 and cytoplasmic
later phase of extrafollicular B cell responses has been immunoglobulin, they die prematurely (Vinuesa et al.,
difficult to assess since neutralization with soluble BAFF 2001). Btk plays a crucial role in BCR-dependent B cell
receptors has profound effects on total peripheral B cell survival through activation of NF-B (Bajpai et al., 2000),
numbers (Schneider et al., 2001; Thompson et al., 2000). which is known to control the expression of Bcl-2 and
Consequently, studies using short-term blockade of Bcl-xL (Karin and Lin, 2002). It seems plausible that the
BAFF and APRIL once normal populations are estab- signaling pathway that leads to NF-B activation is also
lished are required to test their effects on plasmablast involved in transmitting survival signals delivered by
growth and survival. Using such a strategy, Bala´zs et BAFF since BAFF can stimulate expression of Bcl-2 and
al. (2002) show that neutralization of BAFF (with an ade- Bcl-xL (Batten et al., 2000) and BAFF and APRIL cannovirus-expressed TACI-Fc fusion protein) severely im- induce nuclear translocation of NF-B-Rel complexes
pairs antibody responses of mice to killed pneumococci.
(Litinskiy et al., 2002).
This results from impaired plasmablast survival rather
Although the enhancement of the extrafollicular re-
than a defect in plasmablast generation or growth, be-
sponse by BAFF and APRIL has so far only been con-cause TACI-Ig expression does not impair the extrafol-
firmed in responses to T-independent antigen, theselicular antibody response when Bcl-2 is overexpressed
molecules may also augment and strengthen specificby the plasmablasts. The authors also show that the
signals delivered during cognate interaction between Tdendritic cell influencing plasmablast survival is a recent
and B cells and sustain survival of extrafollicular plas-emigrant from the marrow that expresses low levels of
mablasts generated during TD responses. T-indepen-CD11c at the time of immunization. These cells probably
dent B cell activation is crucial for early host defensecorrespond to CD45RA CD11clow CD11b blood mono-
against rapidly dividing pathogens and therefore occu-cytes with immediate dendritic cell precursor potential
pies a place between T-dependent responses and in-(pDC1) (Shortman and Liu, 2002). These cells have been
nate immune responses. The findings of Bala´zs et al.shown to migrate into lymph nodes and produce mature
(2002) provide fresh insight into the way in which TI-2dendritic cells upon phagocytosis of particulate anti-
responses are regulated by innate immune responses.gens or culture with GM-CSF. They differ from the other
Innate augmentation of adaptive TI-2 responses may besubset of blood dendritic cell precursors, known as plas-
lifesaving and hence selectively advantageous, but notmacytoid dendritic cells (pDC2), which are also CD11clow
necessarily risk free. Constitutive overexpression ofbut stain weakly with anti-B220 and anti-Gr1 (Asselin-
BAFF in mice is associated with the development ofPaturel et al., 2001). Plasmacytoid dendritic cells, when
autoantibodies and overt autoimmune disease (Mackayactivated by viral antigens or bacterial CpG, have been
shown to secrete large amounts of interferon-, which and Browning, 2002).
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